3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
6
Gastrointestinal
5
Genitourinary
3
Other solid neoplasm
2
Head & Neck
2
Gynecologic
2
Sarcoma
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
66
Cisplatin
55
Radiotherapy, Intensity-Modulated
28
Carboplatin
27
Nivolumab
26
Paclitaxel
21
Magnetic Resonance Spectroscopy
21
Radiotherapy
20
Cetuximab
16
Specimen Handling
15
Docetaxel
15
Radiation
14
Gemcitabine
13
Fluorouracil
12
Biopsy
12
durvalumab
11
Platinum
11
Taxes
10
Drug Therapy
10
1,2-diaminocyclohexaneplatinum II citrate
10
Surveys and Questionnaires
9
Capecitabine
9
trametinib
8
tislelizumab
6
lenvatinib
6
dabrafenib
6
cemiplimab
6
atezolizumab
6
Radiosurgery
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
zimberelimab
×
Head & Neck
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT06727565
2026-03-02
VELOCITY-HNSCC
Gilead Sciences
Phase 2
Active not recruiting
100 enrolled